-
ASH China Voice | Prof. Yang Liang’s Team Reveals FLT3/ITD-Driven AML Mechanism and New Predictive/Therapeutic Strategies in CLL
From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting was held in Orlando, bringing together the latest global advances in hematologic research and clinical practice. Multiple…
-
ASH China Voice | Jia Wei’s Team Presents Seven Studies at ASH 2025, Advancing Multi-Dimensional Exploration of Therapeutic Bottlenecks in Hematologic
From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting was held in Orlando. As the world’s most influential and comprehensive academic event in hematology, ASH annually gathers tens of thousands of experts to present breakthroughs spanning basic research to clinical innovation. This year, the team led by Professor Jia Wei of…
-
ASH China Voice | Wei Zhang, MD: Novel Loop-Structured CD19/CD22 Dual-Target CAR-T Therapy Brings Breakthrough Hope for Refractory/Relapsed B-NHL
From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting convened in Orlando, attracting tens of thousands of hematology experts worldwide. As the most influential international conference in the field, ASH showcases cutting-edge advances and breakthrough clinical findings each year. At this year’s meeting, an innovative study led by Dr. Wei Zhang…
-
ESMO25 Highlight | Insights from Dr. Darren M. Poon
At the recent ESMO Asia 2025 Congress, a study by Professor Darren Poon’s team at the Hong Kong Comprehensive Oncology Centre was selected, bringing a new precision medicine strategy to patients with advanced prostate cancer. Oncology Frontier- UroStream invited Professor Poon to share his insights on the clinical value and future prospects of liquid biopsy…
-
SIBCS 2025丨Yiding Chen: Two Decades of Surgical Progress in Breast Cancer and a Look Ahead to Precision Treatment
Editor’s Note: The 20th Shanghai International Breast Cancer Symposium (SIBCS), organized by the Shanghai Anti-Cancer Association and the Breast Cancer Professional Committee of the China Anti-Cancer Association, was held in…
-
SIBCS 2025丨Feng Jin: China’s Breast Cancer Clinical Research Enters a New Era of Systematic Innovation Driven by Precision Medicine and Domestic Drug Development
The 20th Shanghai International Breast Cancer Symposium (SIBCS), jointly organized by the Shanghai Anti-Cancer Association and the Breast Cancer Committee of the China Anti-Cancer Association, was recently held in Shanghai. Under the theme “20 Years of Progress, a Future of Continuity”, the forum brought together leading experts from China and abroad to reflect on two…
-
SIBCS 2025丨Jun-jie Li: Riding China’s Wave of Innovation—Leveraging the SIBCS Platform to Drive Comprehensive Advances in Breast Cancer Care
The 20th Shanghai International Breast Cancer Symposium (SIBCS), jointly hosted by the Shanghai Anti-Cancer Association and the Breast Cancer Committee of the China Anti-Cancer Association, was held from November 13–15, 2025 in Shanghai. During the meeting, Professor Jun-jie Li from Fudan University Shanghai Cancer Center delivered a keynote lecture entitled “Two Decades of Shared Progress:…
-
SIBCS 2025 | Professor Kun Wang: Precision Subtyping Drives a New Era of Neoadjuvant Therapy in Breast Cancer—Current Exploration and Future Outlook
The 20th Shanghai International Breast Cancer Symposium (SIBCS), hosted by the Shanghai Anti-Cancer Association and the Breast Cancer Committee of the China Anti-Cancer Association, was held on November 13–15, 2025. During the “Hundred Schools of Thought” session, Professor Kun Wang from Guangdong Provincial People’s Hospital delivered an academic presentation titled “Guangdong Experience: Exploring Neoadjuvant Therapy in the New Era.” Following…
Connecting Medical Expertise through Media